 MR evalu cn tumor comparison studi gadopentet dimeglumin gadoteridol phase II iii trial gadoteridol new nonion low-osmolar contrast agent patient intracrani neoplasm underw magnet reson MR experiment dose mmol/kg fifteen patient underw contrast studi standard dose mmol/kg gadopentet dimeglumin gadopentet dimeglumin gadoteridol similar effect equal dose mmol/kg lesion enhanc delin experiment dose mmol/kg experiment dose mmol/kg quantit analysi lesion ident imag protocol proport relationship lesion contrast ratio dose rang mmol/kg phantom experi clinic result improv enhanc detect delin central nervou system cn inject dose gadoteridol potenti signific possibl cost contrast materi dosag dose adequ evalu cn tumor